Steady-state pharmacokinetics and effects of a new once-daily, slow-release theophylline capsule preparation in asthma

British Journal of Clinical Pharmacology
P E WilliamsI A Campbell

Abstract

Plasma and saliva theophylline concentrations were measured in 21 asthmatic subjects receiving chronic oral therapy with a new sustained-release theophylline capsule (K1B Riker) given as a once daily dose, after titration to achieve a before-dose concentration of 8 mg l-1 or greater, or to the maximum dose of 1200 mg of theophylline daily. Plasma concentrations rose from a mean +/- s.d. minimum concentration (Cmin) of 7.9 +/- 2.3 mg l-1 to a mean maximum of 13.6 +/- 3.3 mg l-1 at a median time of 10 h after dosing. Saliva theophylline concentrations were closely related to the plasma theophylline concentration both between and within subjects with a mean saliva to plasma concentration ratio between subjects (S/P ratio) of 0.62 (+/- 0.05) and a mean within subject coefficient of variation of 8.2% (+/- 4.5%). There was a significant but small (10%) change in the mean S/P ratio during the dosing interval. Peak expiratory flow rate (PEFR) changed slightly but significantly during the dosing interval but forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) did not. The drug was well tolerated at the dose used (600-1200 mg once daily).

References

Jan 1, 1978·Clinical Pharmacokinetics·M Danhof, D D Breimer
Apr 1, 1978·Clinical Pharmacology and Therapeutics·P GalB A Franklin
Aug 1, 1980·British Journal of Clinical Pharmacology·B CusackK O'Malley

❮ Previous
Next ❯

Citations

Nov 1, 1987·British Journal of Clinical Pharmacology·P E WilliamsJ H Lazarus
Jan 1, 1995·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·R B BerkowitzR R Lorber
Jan 1, 1993·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·M J WelchL I Harrison

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

© 2021 Meta ULC. All rights reserved